293 related articles for article (PubMed ID: 26756756)
21. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
[TBL] [Abstract][Full Text] [Related]
22. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis.
Narasimhan V; Tan S; Kong J; Pham T; Michael M; Ramsay R; Warrier S; Heriot A
Colorectal Dis; 2020 Nov; 22(11):1482-1495. PubMed ID: 32027455
[TBL] [Abstract][Full Text] [Related]
24. Extensive surgical history prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with poor survival outcomes in patients with peritoneal mucinous carcinomatosis of appendiceal origin.
Milovanov V; Sardi A; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
Eur J Surg Oncol; 2015 Jul; 41(7):881-5. PubMed ID: 25899982
[TBL] [Abstract][Full Text] [Related]
25. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
[TBL] [Abstract][Full Text] [Related]
26. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
[TBL] [Abstract][Full Text] [Related]
27. [Surgical Management of Peritoneal Surface Malignancy with Respect to Tumour Type, Tumour Stage and Individual Tumour Biology].
Beckert S; Struller F; Grischke EM; Glatzle J; Zieker D; Königsrainer A; Königsrainer I
Zentralbl Chir; 2016 Aug; 141(4):415-20. PubMed ID: 24241953
[TBL] [Abstract][Full Text] [Related]
28. A critical look at local-regional management of peritoneal metastasis.
Chan CH; Cusack JC; Ryan DP
Hematol Oncol Clin North Am; 2015 Feb; 29(1):153-8. PubMed ID: 25475577
[TBL] [Abstract][Full Text] [Related]
29. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).
Milovanov V; Sardi A; Ledakis P; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
Eur J Surg Oncol; 2015 May; 41(5):707-12. PubMed ID: 25633641
[TBL] [Abstract][Full Text] [Related]
30. The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases.
van der Werf LR; Wassenaar E; de Niet A; Lalezari F; Braam HJ; van Ramshorst B; Nederend J; de Hingh IHJT; Kok NFM; Aalbers AGJ
Eur J Surg Oncol; 2019 Mar; 45(3):376-382. PubMed ID: 30414704
[TBL] [Abstract][Full Text] [Related]
31. Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Kuijpers AM; Mehta AM; Aalbers AG; van Driel WJ; Boot H; Verwaal VJ
Eur J Surg Oncol; 2014 Aug; 40(8):937-42. PubMed ID: 24630923
[TBL] [Abstract][Full Text] [Related]
32. [Recurrent Peritoneal Metastases after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer].
Königsrainer I; Struller F; Zieker D; Königsrainer A; Beckert S
Zentralbl Chir; 2015 Dec; 140(6):607-9. PubMed ID: 23846542
[TBL] [Abstract][Full Text] [Related]
33. Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Sluiter NR; de Cuba EM; Kwakman R; Meijerink WJ; Delis-van Diemen PM; Coupé VM; Beliën JA; Meijer GA; de Hingh IH; te Velde EA
Clin Exp Metastasis; 2016 Apr; 33(4):297-307. PubMed ID: 26873137
[TBL] [Abstract][Full Text] [Related]
34. Histologic and Immunohistochemical Alterations Associated with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy.
Wagner P; Boone B; Ramalingam L; Jones H; Zureikat A; Holtzman M; Ahrendt S; Pingpank J; Zeh H; Choudry H; Bartlett D
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S588-95. PubMed ID: 25948159
[TBL] [Abstract][Full Text] [Related]
35. Histological subtype and systemic metastases strongly influence treatment and survival in patients with synchronous colorectal peritoneal metastases.
Simkens GA; Razenberg LG; Lemmens VE; Rutten HJ; Creemers GJ; de Hingh IH
Eur J Surg Oncol; 2016 Jun; 42(6):794-800. PubMed ID: 27055946
[TBL] [Abstract][Full Text] [Related]
36. Cytoreductive surgery (CRS) with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) versus standard of care (SoC) in people with peritoneal metastases from colorectal, ovarian or gastric origin: protocol for a systematic review and individual participant data (IPD) meta-analyses of effectiveness and cost-effectiveness.
Gurusamy K; Vale CL; Pizzo E; Bhanot R; Davidson BR; Mould T; Mughal M; Saunders M; Aziz O; O'Dwyer S
BMJ Open; 2020 May; 10(5):e039314. PubMed ID: 32404398
[TBL] [Abstract][Full Text] [Related]
37. Peritoneal metastases from small bowel cancer: Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in The Netherlands.
van Oudheusden TR; Lemmens VE; Braam HJ; van Ramshorst B; Meijerink J; te Velde EA; Mehta AM; Verwaal VJ; de Hingh IH
Surgery; 2015 Jun; 157(6):1023-7. PubMed ID: 25818658
[TBL] [Abstract][Full Text] [Related]
38. Peritoneal metastases from colorectal cancer: patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Riss S; Mohamed F; Dayal S; Cecil T; Stift A; Bachleitner-Hofmann T; Moran B
Eur J Surg Oncol; 2013 Sep; 39(9):931-7. PubMed ID: 23810280
[TBL] [Abstract][Full Text] [Related]
39. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort.
Frøysnes IS; Larsen SG; Spasojevic M; Dueland S; Flatmark K
J Surg Oncol; 2016 Aug; 114(2):222-7. PubMed ID: 27173150
[TBL] [Abstract][Full Text] [Related]
40. Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy treatment of colorectal peritoneal metastases: cohort analysis of high volume disease and cure rate.
Cashin PH; Dranichnikov F; Mahteme H
J Surg Oncol; 2014 Aug; 110(2):203-6. PubMed ID: 24846340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]